Dataset Information

Development of a chemically modified antisense oligonucleotide that destabilizes the AGO2–miR-204-5p complex as a disease-modifying therapy for osteoarthritis

ABSTRACT: [Background] Osteoarthritis (OA) is a prevalent degenerative joint disease lacking approved disease-modifying therapies. A key pathogenic driver is a senescence-induced microRNA, miR-204-5p, which suppresses glycosaminoglycan-rich proteoglycan anabolism in chondrocytes, transitioning toward a catabolic state that progressively degrades cartilage. This study aimed to evaluate LF-ASO-001, a chemically optimized antisense oligonucleotide designed to potently degrade miR-204-5p, as a potential disease-modifying therapy for OA. [Methods] The structural mechanism of LF-ASO-001 was characterized through molecular docking and molecular dynamics simulations of the Argonaute2 (AGO2)-miR-204-5p complex. To validate its functional activity, we utilized primary murine chondrocytes under stress-induced senescence and miR-204-overexpressing human chondrocytes to assess the restoration of anabolic homeostasis. In vivo pharmacokinetics and safety were profiled via fluorescence-based biodistribution assays and comprehensive toxicity studies. Therapeutic efficacy was evaluated in the murine destabilization of the medial meniscus model. The study design included both an early intervention strategy to assess the prevention of disease progression and a delayed treatment regimen to evaluate the modulation of established pathology following intra-articular administration. [Results] Molecular dynamics simulations revealed that LF-ASO-001 displaces the 3’ end of miR-204-5p from the AGO2 PAZ (Piwi-Argonaute-Zwille) domain, destabilizing the miRNA-loaded complex. LF-ASO-001 suppressed senescence-associated inflammatory and matrix-remodeling phenotypes while restoring anabolic gene expression in senescent chondrocytes. A single intra-articular injection achieved durable cartilage retention and robust efficacy in a post-traumatic OA model in mice. LF-ASO-001 not only prevented joint degeneration but also mitigated established disease in a delayed-treatment model, restoring weight-bearing function. In comparative efficacy studies, LF-ASO-001 provided more robust structural protection than a clinical-stage small-molecule candidate and matched the analgesic benefit of dexamethasone. LF-ASO-001 demonstrated a favorable safety profile, showing no local joint toxicity, adverse effects on serum clinical biochemistry, or alterations in subchondral bone architecture. [Conclusions] LF-ASO-001 is a promising disease-modifying OA drug candidate that couples durable single-dose pharmacology with joint preservation and symptomatic relief through targeted degradation of miR-204-5p via AGO2 complex destabilization.

ORGANISM(S): Homo sapiens

PROVIDER: GSE347205 | GEO | 2026/09/14

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Background/Aim: Transfer RNA-derived fragments (tRFs) are an emerging class of small non-coding RNAs that dynamically respond to metabolic stressors and drive different pathological processes, yet their role in osteoarthritis (OA) remains poorly explored. We aimed to define the tRF landscape in OA and investigate the function of 3′tRFAsp(GTC) in chondrocyte stress adaptation and translational control. Methods: Ex vivo, cartilage specimens from OA patients and healthy donors were analyzed by small RNA sequencing to define disease-associated tRF signatures. In vitro, primary chondrocytes derived from OA patients were treated with lipopolysaccharide (LPS) to mimic the pro-inflammatory environment of OA. Functional studies included antisense oligonucleotide (ASO)-mediated 3′tRFAsp(GTC) inhibition, AGO2-RNA immunopreicipitation (RIP), polysome profiling, stress granule (SG) immunofluorescence, and differential protein analysis. Computational target prediction and pathway enrichment were used to explore tRF-mediated regulatory networks. Results: Both ex vivo OA cartilage and LPS-treated OA chondrocytes displayed upregulation of 3′tRFAsp(GTC) and 5′tRFGlu(CTC), indicating a shared inflammatory tRF signature. Silencing 3′tRFAsp(GTC) attenuated LPS-induced COX2 and MMP13 expression, prevented ER stress, and blocked SG assembly. RIP confirmed selective recruitment of 3′tRFAsp(GTC) into AGO2 complexes. Polysome profiling revealed association with 40S ribosomal subunits, mediating translational arrest and influencing selective mRNA expression. Predicted targets of upregulated tRFs were enriched in stress-adaptive, proteostasis, and translational control pathways, whereas downregulated tRFs modulated mitochondrial processes. Conclusions: 3′tRFAsp(GTC) emerges as crucial regulator linking inflammatory stress to translational control and SG dynamics in OA. tRFs thus could represent a novel therapeutic targets to counteract chronic inflammatory stress in degenerative joint disease.

Dataset Information

Development of a chemically modified antisense oligonucleotide that destabilizes the AGO2–miR-204-5p complex as a disease-modifying therapy for osteoarthritis

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets